The company is substantially boosted this course of the new treatment for ATTR-CM, leveraging the compound. Initial patient results reveals potential outcomes for patients suffering by this serious condition. This emphasis represents BridgeBio's commitment to managing significant patient requirements in a heart disease space. Attruby: BridgeBio's